109 filings
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
10-K/A
2023 FY
LABP
Landos Biopharma Inc
Annual report (amended)
16 Apr 24
8:00am
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
DEFA14A
LABP
Landos Biopharma Inc
26 Mar 24
Additional proxy soliciting materials
8:50am
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
4:01pm
DEFA14A
plp lga7evuml
25 Mar 24
Additional proxy soliciting materials
9:19am
8-K
1yu7zgfy ld99zmqffw
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
S-8
2espo4a
21 Mar 24
Registration of securities for employees
9:12am
8-K
wm7zxz
21 Mar 24
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
8:08am
8-K
nl9ht
4 Jan 24
Regulation FD Disclosure
8:05am
8-K
nu0 fyidkaid
21 Nov 23
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
8:08am
8-K
pbqvr w35pauz2bb26p
9 Nov 23
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
8:08am
8-K
k7fqt
21 Sep 23
Departure of Directors or Certain Officers
8:00am
8-K
u857a9xgr9
14 Sep 23
Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid Models
8:11am
8-K
j63ya lhj2tqi7
9 Aug 23
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
8:12am
8-K
9nhqbgpf7imlt81t u3
30 May 23
Departure of Directors or Certain Officers
4:53pm
8-K
qv4udz9g08yymsezqml5
25 May 23
Landos Biopharma Announces 1-for-10 Reverse Stock Split
4:19pm